Loading...
•
Mar 31, 2025
Immunocore Q1 2025 Earnings Report
Reported first quarter financial results and provided a business update
Key Takeaways
Immunocore reported strong financial performance in the first quarter of 2025, driven by significant growth in KIMMTRAK net product sales. The company achieved profitability for the quarter and maintained a strong cash position to support ongoing clinical development programs.
KIMMTRAK net product sales reached $93.9 million in Q1 2025, a 33% increase year-over-year.
The company achieved a net income of $5.0 million for the quarter, a significant improvement from a net loss in the prior year period.
Cash, cash equivalents, and marketable securities totaled $837.0 million as of March 31, 2025.
Immunocore continues to advance its oncology pipeline with three ongoing Phase 3 trials for KIMMTRAK and brenetafusp.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Immunocore is focused on advancing its clinical pipeline, particularly in oncology and infectious diseases. The company is on track to complete enrollment in the TEBE-AM trial in 1H 2026 and select a dose in the PRISM-MEL-301 trial in 2H 2025. Initial data from the HIV functional cure candidate trial was presented, and further data is expected from the HBV trial in 2H 2025. The company plans to file CTA/IND for two autoimmune candidates in 2H 2025 and 2026.
Positive Outlook
- On track to complete enrollment in Phase 3 TEBE-AM trial in 1H 2026.
- On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025.
- Initial positive multiple ascending dose data for HIV functional cure candidate presented.
- Planning to report data from HBV trial in 2H 2025.
- On track to file CTA/IND for IMC-S118AI (PPI-A02) in 2H 2025.
Challenges Ahead
- No specific negative guidance provided in the report.
- Clinical trial outcomes are subject to risks and uncertainties.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...